Study on prognosis improvement after subarachnoid hemorrhage by CD38

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K18421
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Kanazawa University
• Principal Investigator: Nakao Tsunehito 金沢大学, 医学系, 協力研究員 (60792596)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: くも膜下出血 / 早期脳損傷 / CD38

Outline of Final Research Achievements

After the onset of subarachnoid hemorrhage (SAH), symptomatic cerebral vasospasm occurs in more than 30% of cases. In recent years, the concept of early brain injury (EBI), which occurs within 72 hours after hemorrhage, has attracted attention as a prognostic factor for SAH patients. Therefore, the novel neuroprotective factor CD38 was initiated with the aim of clarifying the molecular mechanism that contributes to amelioration of cerebral vasospasm and brain protection after SAH. We have not been able to elucidate the molecular mechanism that contributes to the protection.

Free Research Field

脳神経外科学

Academic Significance and Societal Importance of the Research Achievements

本研究では、新規神経保護因子 CD38 が、くも膜下出血（subarachnoid hemorrhage : SAH）発症後の脳血管攣縮の改善や脳保護に寄与する分子メカニズムを解明することを目的に開始した。しかし、予定していた評価を十分に進めることができず、TUNEL法や活性化caspase-3 による免疫組織化学を用いた神経細胞死の検出、qRT-PCR や ELISA 法を用いた炎症性サイトカインの検出などでの、SAH の病態評価も十分に進めることはできず、Wild type マウス、CD38 KO マウスでの SAHにおける差は示すことができず、目的を達成できなかった。